WASHINGTON, Feb 1 (Reuters) - Clinical-stage biopharmaceutical company Biolex Inc on Friday canceled a planned initial public offering, citing market conditions.
The company, which had hired Lehman Brothers Inc. and Deutsche Bank Securities Inc to underwrite the IPO, notified the Securities and Exchange Commission of its plans to withdraw its IPO documents. <<
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”